Bristol Myers Squibb Posts 2025 Results, Raises Dividend

Bristol-Myers Squibb ( (BMY) ) has provided an update.

On February 5, 2026, Bristol Myers Squibb reported its fourth-quarter and full-year 2025 financial results, showing modest top-line performance but strong contributions from its newer medicines. Fourth-quarter revenues in 2025 rose 1% year-on-year to $12.5 billion as Growth Portfolio sales grew 16% to $7.4 billion, offsetting a 15% decline in the Legacy Portfolio, while GAAP EPS came in at $0.53 and non-GAAP EPS at $1.26, both reflecting a negative earnings impact from acquired in-process R&D charges and licensing income. For full-year 2025, revenues were essentially flat at $48.2 billion, but profitability improved sharply, with GAAP EPS of $3.46 and non-GAAP EPS of $6.15, and management highlighting disciplined execution, a strengthened balance sheet and strong momentum in core franchises such as immuno-oncology, Camzyos, Breyanzi and Reblozyl. Looking ahead, the company issued 2026 guidance calling for revenues of about $46.0 billion to $47.5 billion and non-GAAP EPS of $6.05 to $6.35, and underscored its confidence in a “data-rich” year with multiple pivotal pipeline readouts, while continuing its shareholder return strategy by raising the quarterly dividend to $0.63 per share, marking the 17th consecutive annual increase.

The most recent analyst rating on (BMY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.

Spark’s Take on BMY Stock

According to Spark, TipRanks’ AI Analyst, BMY is a Outperform.

The score is driven primarily by strong operating profitability and cash generation alongside improving net margins, tempered by high leverage. Technicals are constructive with the stock trading above key moving averages and positive MACD. Valuation is reasonable with an above-average dividend yield, and the latest earnings call was supportive due to raised revenue guidance and strong growth-portfolio momentum despite adoption and policy-related uncertainties.

To see Spark’s full report on BMY stock, click here.

More about Bristol-Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines, with a portfolio spanning immuno-oncology and other specialty therapies. Its revenues are driven by a Growth Portfolio that includes key products such as Opdivo, Yervoy, Orencia, Reblozyl and newer launches, alongside a Legacy Portfolio that faces ongoing generic competition and pricing pressures, particularly in the U.S.

Average Trading Volume: 14,377,394

Technical Sentiment Signal: Strong Buy

Current Market Cap: $117.3B

See more data about BMY stock on TipRanks’ Stock Analysis page.